Guest Writer

The four reasons private equity must “stage” assets

Few sponsors take a final look at what can be improved operationally and financially to generate stronger returns as they prepare to sell.

The booming e-sports industry nears an inflection point

If it surprises you that video game contests are attracting as many viewers as the Super Bowl on a global scale, you probably haven’t been paying close attention to the dramatic rise of e-sports in recent years.

Are companies targeted by SPACs ready for the next steps?

A growing number of SPAC sponsors are requiring target companies to undergo IPO readiness assessments.

Investors are piling into healthcare AI start-ups; there’s room for more

Jason Schoettler of Calibrate Ventures talks about the potential for growth in healthtech and how it's attracting plenty of venture investors with their eyes on the $800bn US healthcare industry.

Gen II: The emerging manager market is poised for growth

A re-emergence for emerging managers is under way, writes Gen II Fund Services principal Jeff Gendel.

Technology adoption reluctance in PE: demystifying the top five objections

Enlightened funds no longer see tech as a luxury, but rather as mission critical to attracting investment, winning deals, extracting maximum portfolio value and delivering results.

Best practices for serving on corporate investment committees

Scott Lenet of Touchdown Ventures talks about the crucial role of the corporate investment committee in venture capital.

Companies benefit in myriad ways from the exponential growth of private equity

Companies have more options than ever before to access private capital across debt, minority or majority equity investments.

The rise of Southeast Asia’s $1trn tech economy

Amit Anand of Jungle Ventures peers behind the curtain of Southeast Asia and calls it the world’s next great digital economy hub.

De-mystifying the de-SPAC: regulation and risk in life sciences transactions

For the SPAC sponsor, without the benefit of the portfolio risk management of a venture fund, the risk-reward profile for a private biotech acquisition is not for the faint of heart.